|Bid||14.61 x 300|
|Ask||14.87 x 900|
|Day's Range||14.59 - 15.70|
|52 Week Range||4.41 - 16.06|
|PE Ratio (TTM)||-9.97|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||16.25|
NEW YORK, NY / ACCESSWIRE / September 21, 2017 / U.S. markets closed at another record high on Wednesday as bank stocks surged after the Federal Reserve announcement kept the possibility of a December ...
CRANBURY, N.J., Sept. 21, 2017-- Amicus Therapeutics today announced the U.S. FDA has granted orphan drug designation to ATB200/AT2221 for the treatment of Pompe disease, an inherited lysosomal storage ...
CRANBURY, N.J., Sept. 20, 2017-- Amicus Therapeutics announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners ...